The government has selected 55 manufacturers in three categories out of 278 applications received under the PLI Scheme for the pharmaceutical sector.

The scheme covers three different product categories for which applicants have applied under the scheme. These products are expected to give an impetus to innovation, R&D and widening of the product profile of the India Pharmaceutical industry. 

In Group A, 11 companies were selected. The category comprises Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell-based or gene therapy drugs; Orphan drugs; Special empty capsules like HPMC, Pullulan, enteric etc.; Complex excipients; and Phyto-pharmaceuticals.

In Group B, 9 companies were selected. The category comprises Active Pharmaceutical Ingredients/Key Starting materials/Drug Intermediates (except the Active Pharmaceutical Ingredients/Key Starting materials/Drug Intermediates covered under the earlier PLI scheme for APIs/KSMs and DIs being implemented by the department).

Selected Manufacturers in Group A

1. Sun Pharmaceutical Industries Limited

2. Aurobindo Pharma Limited

3. Dr. Reddy’s Laboratories Limited

4. Lupin Limited

5. Mylan Laboratories Limited

6. Cadila Healthcare Limited

7. Cipla Limited

8. Amneal Pharmaceuticals Private Limited

9. Glenmark Pharmaceuticals Limited

10. Intas Pharmaceuticals Limited

11. Torrent Pharmaceuticals Limited

Selected Manufacturers in Group B

1. Biocon Limited

2. MSN Laboratories Private Limited

3. Wockhardt Limited

4. Alembic Pharmaceuticals Limited

5. Emcure Pharmaceuticals Limited

6. Macleods Pharmaceuticals Ltd. 

7. Biological E Limited

8. Natco Pharma Limited

9. Strides Pharma Science Limited

Selected Manufacturers in Group C

1. Vindhya Pharma (India) Private Limited

2. Aarti Industries Limited

3. Symbiotec Pharmalab Private Limited

4. Transasia Bio-Medicals Limited

5. Sai Life Sciences Limited

6. Poly Medicure Limited

7. Concord Biotech Limited

8. Amoli Organics Private Limited

9. BDR Pharmaceuticals International Private Limited

10. Malladi Drugs & Pharmaceuticals Limited

11. Symed Labs Limited

12. Bal Pharma Limited

13. Acme Formulation Private Limited

14. Panacea Biotec Limited

15. Abhilash Life Sciences LLP

16. Neogen Chemicals Limited

17. Biophore India Pharmaceuticals Private Limited

18. Nosch Labs Private Limited

19. Aragen Life Sciences Private Limited

20. Sri Krishna Pharmaceuticals Limited

21. Optimus Drugs Private Limited

22. Venus Remedies Limited

23. Psychotropics India Limited

24. Steril-Gene Life Sciences Private Limited

25. Aurore Life Sciences Private Limited

26. Milan Laboratories India Private Limited

27. Vandana Life Science Private Limited

28. Nitika Pharmaceutical Specialities Private Limited

29. Hy-Gro Chemicals Pharmtek Private Limited

30. Mendas Pharma Private Limited

31. Optimus Pharma Private Limited

32. Maiva Pharma Private Limited

33. Trivitron Healthcare Private Limited

34. Agappe Diagnostics Limited

35. Premier Medical Corporation Private Limited

In Group C, 35 companies were selected of which 20 are MSMEs. The category comprises Repurposed drugs; Autoimmune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and antiretroviral drugs; In vitro diagnostic devices; Other drugs not manufactured in India.

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme. The selection of applicants in each of the three categories has been approved by the Minister for Chemicals and Fertilizers.

With this announcement, a major thrust in investment is expected by the pharmaceutical industry which is ultimately aimed at meeting the objectives of the scheme.

The objective of the scheme is to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. One of the further objectives of the scheme is to create global champions out of India who has the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.